We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




A Drug That Prevents Lung Damage Protects Mice with Influenza Infection

By LabMedica International staff writers
Posted on 16 Jun 2015
Print article
A novel approach for treating infection by the influenza virus focuses on strengthening the small blood vessels in the lung of the victim so they do not leak fluids, which can lead to respiratory failure.

Seasonal influenza virus infections cause hundreds of thousands of deaths annually while viral mutation raises the threat of the emergence of a novel pandemic strain. Severe influenza virus infections are complicated by respiratory failure due to the development of microvascular leaks that lead to acute lung injury. Antiviral drugs exhibit limited efficacy unless administered early and may induce viral resistance. For these reasons targeting the host response directly has been proposed as a novel therapeutic strategy with the added potential benefit of not eliciting viral resistance.

To test the potential therapeutic benefits of enhancing lung endothelial barrier integrity, investigators at St. Michael's Hospital (Toronto, Canada) treated influenza infected mice with the drug Vasculotide. This drug is a synthetic peptide-based growth factor that targets Tie-2, a receptor on specialized cells of the hematopoietic and vascular systems. Tie-1 and Tie-2 comprise the cell-surface receptors that bind and are activated by the angiopoietins, (Ang1, Ang2, Ang3, and Ang4). The angiopoietins are protein growth factors required for the formation of blood vessels.

Results published in the June 5, 2015, online edition of the journal Scientific Reports, revealed that Vasculotide improved survival in mouse models of severe influenza, even if administered as late as 72 hours after infection. In one study 100% of infected mice died within one week, while more than 80% of a similar group treated with Vasculotide survived.

The benefits of the drug were observed using three strains of the virus and two strains of mice. The effect required Tie2, was independent of viral replication, and did not impair lung neutrophil recruitment.

Senior author Dr. Warren Lee, a cell biologist at St. Michael's Hospital, said, "While this research was conducted in mice, the results were exciting, since the drug was effective in two different strains of mice and three different strains of flu. Since the mechanism of blood vessels leaking into lungs is common throughout animals, I am optimistic the drug could be effective in animals other than mice, including humans."

Related Links:

St. Michael's Hospital


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.